Maximum Deduction. Notwithstanding anything to the contrary herein, under no circumstances shall the combined effect of all reductions to the Royalties permitted under Sections 3.5.1 and 3.5.2, on a country-by-country and Licensed Product-by-Licensed Product basis, reduce the effective Royalties payable by Licensee to Pieris under this Agreement for any Calendar Quarter below [***] of the Royalties that would otherwise be payable pursuant to Section 3.4, as applicable, for such Licensed Product in such country.
Appears in 2 contracts
Samples: Non Exclusive License Agreement (Pieris Pharmaceuticals, Inc.), Non Exclusive License Agreement (Pieris Pharmaceuticals, Inc.)
Maximum Deduction. Notwithstanding anything to the contrary herein, under no circumstances shall the combined effect of all reductions to the Royalties permitted under Sections 3.5.1 4.1.1 and 3.5.24.1.2.(a), on a country-by-country and Licensed Product-by-Licensed Product basis, reduce the effective Royalties payable by Licensee Servier to Pieris under this Agreement for any Calendar Quarter [***] below [***] of the Royalties that would otherwise be payable pursuant to Section 3.42.6.6 and Section 3.6.4, as applicable, for such Licensed Product in such country.
Appears in 2 contracts
Samples: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.), License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)
Maximum Deduction. Notwithstanding anything to the contrary herein, under no circumstances shall the combined effect of all reductions to the Royalties permitted under Sections Section 3.5.1 and Section 3.5.2, on a country-by-country and Licensed Product-by-Licensed Product basis, reduce the effective Royalties payable by Licensee to Pieris under this Agreement for any Calendar Quarter below [***] percent ([***]%) of the Royalties that would otherwise be payable pursuant to Section 3.4, as applicable, for such Licensed Product in such country.
Appears in 2 contracts
Samples: Non Exclusive License Agreement (Pieris Pharmaceuticals, Inc.), Non Exclusive Anticalin Platform Technology License Agreement (Pieris Pharmaceuticals, Inc.)